24/7 Market News Snapshot 03 June, 2025 – Kiora Pharmaceuticals, Inc. Common Stock (NASDAQ:KPRX)

June 3, 2025

DENVER, Colo., 03 June, 2025 (www.247marketnews.com) – (NASDAQ:KPRX) are discussed in this article.
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) recently demonstrated a notable upsurge in pre-market trading, with shares climbing 7.05% to $3.051 from the previous close of $2.850. This increase was backed by a substantial trading volume of 861.55K shares, showcasing considerable investor enthusiasm and suggesting the potential for continued momentum. Technical analysis points to a possible breakout, with critical resistance levels identified around $3.20. However, traders are advised to remain vigilant for any signs of reversal as they monitor support levels.

In another significant development, Kiora Pharmaceuticals announced an exclusive option agreement with Senju Pharmaceutical Co., Ltd., extending Senju’s rights to develop and commercialize KIO-301 for various ophthalmic diseases, particularly retinitis pigmentosa. This agreement could exceed a total deal value of $110 million, complemented by tiered royalties on future sales, marking a pivotal step in Kiora’s strategic global partnerships.

Kiora will receive an immediate $1.25 million upfront fee for this exclusive option. Should Senju proceed to exercise its option, Kiora is set to gain additional mid-single-digit million payments tied to development, regulatory milestones, and commercial achievements. CEO Brian Strem emphasized the transformative potential of KIO-301, a groundbreaking therapy aimed at treating inherited retinal diseases, highlighting how this collaboration not only enhances Kiora’s market presence but also fulfills a significant need for innovative treatment options.

KIO-301, currently undergoing Phase 2 clinical trials, functions as a “molecular photoswitch” targeted at preserving retinal ganglion cells, holding promise for restoring vision in patients affected by severe retinal degeneration. This partnership with Senju complements Kiora’s existing collaboration with Théa, further solidifying its position as a leader in developing advanced therapeutic options for retinal conditions on a global scale.

Related news for (KPRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.